# EDGAR Filing Document

**Accession Number:** 0002044725
**File Stem:** 0001193125-25-283141
**Filing Date:** 2025-11
**Character Count:** 14482
**Document Hash:** e876eec4009a43c35a11da8d5a94b619
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-283141.hdr.sgml**: 20251114

**ACCESSION NUMBER**: 0001193125-25-283141

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20251114

**DATE AS OF CHANGE**: 20251114

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evommune, Inc.
- **CENTRAL INDEX KEY:** 0002044725
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 850742575
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95351
- **FILM NUMBER:** 251487138

**BUSINESS ADDRESS:**
- **STREET 1:** 1841 PAGE MILL RD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** (650) 223-7745

**MAIL ADDRESS:**
- **STREET 1:** 1841 PAGE MILL RD
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LSP 7 Cooperative UA
- **CENTRAL INDEX KEY:** 0001876264

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** JOHANNES VERMEERPLEIN 9
- **CITY:** AMSTERDAM
- **PROVINCE COUNTRY:** P7
- **BUSINESS PHONE:** 31206645500

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** JOHANNES VERMEERPLEIN 9
- **CITY:** AMSTERDAM
- **PROVINCE COUNTRY:** P7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LSP Cooperative UA
- **DATE OF NAME CHANGE:** 20210802

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99_1.pdf`

_No text found in this document._

**Attachment 2:** `ck0000000000-ex99_3.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Evommune, Inc.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**30054Y107**

*(CUSIP Number)*

**Bas Vaessen**<br>LSP 7 Management B.V.<br>Johannes Vermeerplein 9<br>Amsterdam P7 1071 DV<br>31 20 664 5500

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**11/07/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **30054Y107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**LSP 7 Cooperatieve U.A.** | Name of reporting person<br>**LSP 7 Cooperatieve U.A.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**P7** | Citizenship or place of organization<br>**P7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4929633.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4929633.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4929633.00** | Aggregate amount beneficially owned by each reporting person<br>**4929633.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**15.7%** | Percent of class represented by amount in Row (11)<br>**15.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **30054Y107** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**LSP 7 Management B.V.** | Name of reporting person<br>**LSP 7 Management B.V.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**P7** | Citizenship or place of organization<br>**P7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**4929633.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**4929633.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4929633.00** | Aggregate amount beneficially owned by each reporting person<br>**4929633.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**15.7%** | Percent of class represented by amount in Row (11)<br>**15.7%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
Evommune, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
1841 Page Mill Road, Suite 100, Palo Alto, CA, 94304

**Item 4. Purpose of Transaction**

Third Amended and Restated Investors' Rights Agreement

On October 30, 2024, certain investors of the Issuer, including LSP 7, entered into a third amended and restated investors' right agreement (the "Investors' Rights Agreement") with the Issuer, pursuant to which the Issuer agreed to register for resale certain shares of Common Stock and other equity securities of the Issuer that are held by the parties (the "Registrable Securities"), and agreed to provide customary "piggyback" registration rights, subject to certain requirements and conditions.

Pursuant to the Investors' Rights Agreement, beginning 180 days after the effective date of the registration statement filed in connection with the IPO, the Issuer will file a registration statement registering the resale of the Registrable Securities upon the request of holders of at least a majority of the outstanding Registrable Securities. The investors may only request up to two registrations. In addition, holders of at least 20% of the outstanding Registrable Securities may request the Issuer to file a registration statement on Form S-3, if eligible, to sell Registrable Securities with an anticipated aggregate offering amount of at least $5.0 million net of certain expenses related to the offering. The investors may only request up to two registration statements on Form S-3 in a 12-month period. The Issuer will be responsible for certain expenses relating to such registrations and indemnify the stockholders against certain liabilities.

The registration rights granted under the Investors' Rights Agreement will terminate upon the earlier of (i) a deemed liquidation event or certain other events constituting sale of the Issuer, (ii) at such time after the IPO when all Registrable Securities could be sold under Rule 144 of the Securities Act of 1933, as amended, or a similar exemption without limitation during a three-month period without registration or (iii) the fifth anniversary of the IPO.

Lock-up Agreement

In connection with the IPO, LSP 7 entered into an agreement (the "Lock-Up Agreement") that for a period of 180 days following the Closing Date, subject to certain exceptions, it will not offer, sell, assign, transfer, pledge, contract to sell or otherwise dispose of or hedge any shares of Common Stock or any securities convertible into or exchangeable for shares of Common Stock.

The foregoing descriptions of the Investors' Rights Agreement and the Lock-Up Agreement do not purport to be complete and are qualified in their entirety by the full text of such agreements, which are attached as exhibits to this Schedule 13D and incorporated herein by reference.

General

The Reporting Persons intend to review their investments in the Issuer on a continuing basis. Any actions the Reporting Persons might undertake may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Persons' review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer's business, financial condition, operations and prospects; price levels of the Issuer's securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments.

The Reporting Persons, subject to the Lock-Up Agreement, may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. In addition, the Reporting Persons, including their designee to the Issuer's board of directors (the "Board"), Felice Verduyn-van Weegen, may engage in discussions with management, the Board, other securityholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary corporate transactions, such as: a merger, reorganization or take-private transaction that could result in the de-listing or de-registration of the Common Stock; sales or acquisitions of assets or businesses; changes to the capitalization or dividend policy of the Issuer; or other material changes to the Issuer's business or corporate structure, including changes in management or the composition of the Board.

To facilitate their consideration of such matters, the Reporting Persons may retain consultants and advisors and may enter into discussions with potential sources of capital and other third parties. The Reporting Persons may exchange information with any such persons pursuant to appropriate confidentiality or similar agreements. The Reporting Persons will likely take some or all of the foregoing steps at preliminary stages in his consideration of various possible courses of action before forming any intention to pursue any particular plan or direction.

Other than as described above, the Reporting Persons do not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Persons may change their purpose or formulate different plans or proposals with respect thereto at any time.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The ownership information presented herein represents beneficial ownership of Common Stock as of the date hereof, based on 31,483,810 shares of Common Stock outstanding as of the date of this filing.

LSP 7 is the record holder of the shares of Common Stock reported herein and is the beneficial owner of approximately 15.7% of the outstanding shares of Common Stock. LSP 7 Management B.V. is the sole director of LSP 7. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe.

**(b)**
Sole power to vote or to direct the vote: 0

Shared power to vote or to direct the vote: 4,929,633

Sole power to dispose or to direct the disposition of: 0

Shared power to dispose or to direct the disposition of: 4,929,633

**(c)**
Except as set forth in this Schedule 13D, during the past 60 days, none of the Reporting Persons nor the Related Persons have effected any transactions in the Common Stock.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Item 4 above summarizes certain provisions of the Investors' Rights Agreement and the Lock-Up Agreement and is incorporated herein by reference. A copy of each such agreement is attached as an exhibit to this Schedule 13D and is incorporated by reference herein.

Except as set forth herein, none of the Reporting Persons has any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** LSP 7 Cooperatieve U.A.

**Signature:** By: LSP 7 Management B.V., its sole director, By: /s/ Martijn Kleijwegt

**Name/Title:** Martijn Kleijwegt, Managing Director

**Date:** 11/14/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** LSP 7 Management B.V.

**Signature:** /s/ Martijn Kleijwegt

**Name/Title:** Martijn Kleijwegt, Managing Director

**Date:** 11/14/2025